First umbilical cord mesenchymal stem cell treatment in U.S.A.

After FDA Approval, Duchenne’s Muscular Dystrophy Patient Receives First Umbilical Cord Stem Cell Treatment in the United States

Ryan Benton, a 28 year-old Duchenne’s muscular dystrophy patient from Wichita, Kansas, received his first umbilical cord tissue-derived mesenchymal stem cell treatment yesterday following US FDA approval of his doctor’s application for a single patient, investigational new drug (IND) for compassionate use.

Duchenne muscular dystrophy (DMD) is a rapidly progressive form of muscular dystrophy that occurs primarily in boys. It is caused by an alteration (mutation) in a gene, called the DMD gene, which causes the muscles to stop producing the protein dystrophin. Individuals who have DMD experience progressive loss of muscle function and weakness, which begins in the lower limbs and leads to progressively worsening disability. Death usually occurs by age 25, typically from lung disorders. There is no known cure for DMD.

This trial, officially entitled “Allogeneic transplantation of human umbilical cord mesenchymal stem cells (UC-MSC) for a single male patient with Duchenne Muscular Dystrophy (DMD)” marks the first time the FDA has approved an investigational allogeneic stem cell treatment for Duchenne’s in the United States.

Ryan received his first intramuscular stem cell injections from allergy and immunology specialist, Van Strickland, M.D at Asthma and Allergy Specialists in Wichita, Kansas. He will receive 3 more treatments this week on consecutive days. Dr. Strickland will administer similar courses to Ryan every 6 months for a total of 3 years.

This is not the first time Ryan has undergone umbilical cord mesenchymal stem cell therapy. Since 2009, Ryan has been traveling to the Stem Cell Institute in Panama for similar treatments. Encouraging results from these treatments prompted Dr. Strickland to seek out a way to treat Ryan in the United States.

The stem cell technology being utilized in this trial was developed by renowned stem cell scientist Neil H. Riordan, PhD. Dr. Riordan is the founder and president of the Stem Cell Institute in Panama City, Panama and Medistem Panama. Medistem Panama is providing cell harvesting and banking services for their US-based cGMP laboratory partner.

Funding for this trial is being provided by the Aidan Foundation, a non-profit organization founded by Dr. Riordan in 2004 to provide financial assistance for alternative therapies to people like Ryan.

Read more: http://www.digitaljournal.com/pr/2178513#ixzz3D3rUBmA2

Read more: http://www.digitaljournal.com/pr/2178513#ixzz3D3rN8uGW

http://www.digitaljournal.com/pr/2178513

Stage IV Lung Cancer Patient Still Benefiting from Dendritic Cell Vaccine 15 Years Later

I received this forwarded email today from the nephew of a patient who was in our clinical trial in 1998-1999 using dendritic cells. We had tried to follow up with her but could not locate her due to a move.

The dendritic cell vaccine that was used on her was the subject of the patent cited below.

June 7, 2014

Dear Riordan Clinic Researchers

I am writing to you in regards to research that you did in 1998-1999. I know that in dealing with cancer patients you must encounter many sad stories, so I thought you would like to hear one with a happy ending. I have looked on your web page and I don’t see that you are still doing research on this project but I thought you would be interested in the results anyway…..maybe they will spark a new research project.

My mother passed away a while back and I have been going through her papers. She saved all the information on my aunt’s (her sister) cancer treatment so I can actually give you accurate details below.

In the fall of 1998 my Aunt, XXX XXXXX was diagnosed with non-small cell lung cancer. She lived in Canada at the time but chose to go to the Mayo Clinic in Minnesota for radiation treatment since she felt their machines were better. The Mayo Clinic determined that there was a mass of large cell carcinoma, metastic grade 4 which had grown so large that it had fractured her clavicle. They knew this was not the site of the primary tumor but were not able to identify the primary location. There were multiple small tumors scattered throughout the area.

She chose to have radiation treatments of the tumor below the clavical. She then visited the Garvey Institute in Kansas, for what the papers I have call leukapheresis procedure. I know she collected her urine for a number of days and that somehow parts of it were extracted and perhaps parts of blood samples were used also. From this a fluid using the patient’s own tumor material and dendritic cells was made. I assume the study she was a part of was not FDA approved because she had to go to San Jose, Costa Rica to be injected with the finished extract. When she returned home to Canada she followed an organic juicing diet for a period of time.

That was now 15 years ago. My aunt is now 76 years old and still alive and well with no current sign of cancer. Since this time she and my uncle have built a new home in Canada, sold that home, and have moved to Costa Rica full time. She hikes and enjoys all kinds of outdoor activities. They eat a primarily vegetarian diet, supplemented with chicken and fish. They spent a couple weeks with us in California last summer and this fall we hope to make our first trip to visit them in Costa Rica. I have always been surprised that the Garvey Clinic never did follow up questionnaires (sic) with her to see how she was doing since she was such a success story. She proves that even someone with stage 4 metastatic can should not give up hope and should look for treatments that have the potential to help or cure them.

I am sure that information on her diagnosis and treatment must be in your records, but I do have copies of the material she was given, if anyone wants more information.

Sincerely,

XXX

United States Patent 7,749,495
Riordan July 6, 2010
Method for inducing an anti-tumor and anti-cachexia immune response in mammals

Abstract
The invention relates to inducing an immune response toward tumor associated antigens and in particular to the administration of high molecular weight isolates of autologous urine either alone, with adjuvants, or with antigen presenting cells. The antigen presenting cells have been cocultured with isolates of autologous urine. The invention can also be used to treat cachexia in cancer or AIDS patients.

Inventors: Riordan; Neil H. (Chandler, AZ)
Assignee: Aidan, Inc. (Tempe, AZ)
Family ID: 26920848
Appl. No.: 12/126,744
Filed: May 23, 2008

Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis

Press release Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board Translational Biosciences, a subsidiary of Medistem Panama has … [Continue reading]